ADVFN ADVFN

Hot Features

Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Cansino Biologics Inc (PK)

Cansino Biologics Inc (PK) (CASBF)

2,60
0,00
(0,00%)
Fermé 12 Juillet 10:00PM

Cansino Biologics Inc (PK) (CASBF) Action

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Statistiques et détails clés

Dernier
2,60
( - )
Prix Achat
2,53
Prix Vente
3,42
Volume échangé
-
Volume moyen (3 m)
US$ 1 031 481
Volume financier
-
0,00 Fourchette du Jour 0,00
2,60 Plage de 52 semaines 6,99
Cap du marché
Valeur d'Entreprise
7,191B
Clôture Veille
2,60
Ouverture
-
Dernière Transaction
Dernière heure de transaction
VWAP
-
Chiffre d'affairess (LTM)
1,12B
Bénéfice net (LTM)
-1,01M
Actions en circulation
247 043 801
Flottant (%)
64,72%
Détention Institutionnelle (%)
8,13%
Rendement du Dividende (LTM)
Ratio Cours sur Bénéfices
-5,15k
Ratio Cours/Ventes (P/S)
7,53
Bénéfice par action (BPA)
-0
Bêta
1,2

À propos de Cansino Biologics Inc (PK)

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningit... CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; and CS-2023 to treat meningitis. The company was incorporated in 2009 and is headquartered in Tianjin, the People’s Republic of China. Show more

Secteur
-
Industrie
-
Site Web
Siège social
Tianjin, China
Fondé
2026
Cansino Biologics Inc (PK) est coté dans le secteur de la OTC Markets avec le ticker CASBF. Le dernier cours de clôture d'Cansino Biologics (PK) était de US$2,60. Au cours de la dernière année, les actions de Cansino Biologics (PK) ont été négociées dans une fourchette de prix de US$ 2,60 à US$ 6,99.

Cansino Biologics (PK) compte actuellement 247 043 801 actions en circulation. La capitalisation boursière d'Cansino Biologics (PK) est de US$642,31 million. Cansino Biologics (PK) a un ratio cours/bénéfice (ratio PE) de -5,153.58.

CASBF Dernières nouvelles

Aucune actualité à afficher pour le moment.
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1002.62.62.62002.6CS
4-0.26-9.090909090912.862.862.61332.665CS
12-1.26-32.64248704663.8642.64363.48577982CS
26-2.145-45.20547945214.7454.7452.63713.66320498CS
52-2.4-4856.992.614944.38147055CS
156-0.9-25.71428571433.56.991.8618483.38157845CS
260-38.19-93.625888698240.7949.021.86231915.31132774CS

CASBF - Frequently Asked Questions (FAQ)

What is the current Cansino Biologics Inc (PK) share price?
The current share price of Cansino Biologics Inc (PK) is US$ 2,60
How many Cansino Biologics Inc (PK) shares are in issue?
Cansino Biologics Inc (PK) has 247 043 801 shares in issue
What is the market cap of Cansino Biologics Inc (PK)?
The market capitalisation of Cansino Biologics Inc (PK) is USD 642,31M
What is the 1 year trading range for Cansino Biologics Inc (PK) share price?
Cansino Biologics Inc (PK) has traded in the range of US$ 2,60 to US$ 6,99 during the past year
What is the PE ratio of Cansino Biologics Inc (PK)?
The price to earnings ratio of Cansino Biologics Inc (PK) is -5,15k
What is the cash to sales ratio of Cansino Biologics Inc (PK)?
The cash to sales ratio of Cansino Biologics Inc (PK) is 7,53
What is the registered address of Cansino Biologics Inc (PK)?
The registered address for Cansino Biologics Inc (PK) is 401-420, Biomedical Park, Tianjin, 300457
What is the Cansino Biologics Inc (PK) website address?
The website address for Cansino Biologics Inc (PK) is cansinotech.com

CASBF Transactions

Plus

Transactions différées

Pour obtenir des transactions en temps réel, améliorez votre compte

Passer à la version en temps réel
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock